Participants 121 172 8
patients with senile dementia of the Alzheimer type
Participants 609 653 3
ouble-blind, randomized, multicenter study c
Participants 863 922 5
patients with mild to moderate probable Alzheimer's disease
Participants 935 981 9
204 patients with probable Alzheimer's disease
Participants 1020 1214 8
136 patients were eligible for the according-to-protocol analysis of efficacy, 167 subjects for the intention-to-treat analysis of efficacy, and 181 patients were included in the safety analysis
Participants 1478 1491 3
placebo group
